Palvella Therapeutics
PVLA
41 hedge funds and large institutions have $143M invested in Palvella Therapeutics in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 7 closing their positions.
2,700% more call options, than puts
Call options by funds: $56K | Put options by funds: $2K
196% more capital invested
Capital invested by funds: $48.4M → $143M (+$95M)
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
24% more funds holding
Funds holding: 33 → 41 (+8)
9.72% more ownership
Funds ownership: 35.95% → 45.66% (+9.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.74M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.32M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.45M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
-$2.12M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$1.74M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$542K |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$506K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$125K |
PVLA Hedge Fund Activity: Q1 2025 in Review
41 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2025, worth a combined $143M — up 196% from $48.4M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PVLA positions and 7 closed out — a net gain of 8 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $5.2M. The largest seller was Blue Owl Capital Holdings, cutting an estimated $2.12M.
- 41 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2025, up from 33 in Q4 2024.
- Funds reported $143M of Palvella Therapeutics stock for Q1 2025, up 196% quarter-over-quarter.
- 15 funds opened new Palvella Therapeutics positions in Q1 2025 and 7 closed out, a net change of +8 holders.
- The largest Palvella Therapeutics buyer in Q1 2025 was Millennium Management, an estimated $5.2M added.
- The largest Palvella Therapeutics seller in Q1 2025 was Blue Owl Capital Holdings, an estimated $2.12M sold.
Based on aggregated 13F filings for Q1 2025.